The Effect of Voglibose on Metabolic Profiles in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Clinical Trials Publisher Pubmed



Nowrouzisohrabi P¹ ; Tabrizi R² ; Rezaei S³ ; Jafari F² ; Hesami K⁴ ; Abedi M⁵ ; Jalali M⁶ ; Keshavarzi P² ; Shahabi S² ; Kolahi AA⁷ ; Carsonchahhoud K⁸ ; Sahebkar A^{9, 10, 11} ; Safiri S^{12, 13, 14} Show Affiliations
Source: Pharmacological Research Published:2020

Abstract

Objective: The effect of voglibose on metabolic homeostasis is not well characterized. Therefore, we conducted a systematic review and meta-analysis of clinical trials assessing the effect of voglibose on metabolic profile in patients with type 2 diabetes mellitus (T2DM). Methods: Systematic searches were conducted in PubMed, Scopus, Embase, Google Scholar, Web of Science and Cochrane Library to identify clinical trials assessing the effects of voglibose supplementation on cardio-metabolic profile from incept up to 29 July 2019. Data was pooled using fixed- or random-effect models and weighted mean difference (WMD) as the effect size. Results: Eight clinical trials from 1094 reports, were eligible for inclusion. Pooled findings identified significant reductions in hemoglobin A1c (HbA1c) (WMD= −0.27; 95 %CI −0.49 to −0.05; P = 0.01; I2 = 64.8 %) and an increase in LDL-cholesterol levels (WMD=5.97 mg/dl, 95 % CI 0.88, 11.06, P = 0.02; I2 = 0.0 %). However, no evidence of effect for voglibose intake on T2DM patients was observed for: fasting blood sugar (FBS) (WMD −7.43 mg/dl; 95 %CI -16.56 to 1.71; P = 0.110; I2 = 69.3 %), serum insulin (WMD= −0.15 μU/mL; 95 %CI −0.89 to 0.60; P = 0.70; I2 = 0.0 %), total-cholesterol (WMD=2.82 mg/dl, 95 %CI -2.36 to 8.01, P = 0.70; I2 = 49.7 %), triglycerides (WMD= −7.07 mg/dl, 95 %CI −21.76 to 7.62, P = 0.34; I2 = 0.0 %), HDL-cholesterol levels (WMD= −2.10 mg/dl, 95 %CI −4.48 to 0.27, P = 0.08; I2 = 0.0 %,), body mass index (BMI) (WMD=0.09 kg/m2, 95 %CI −0.70 to 0.87; P = 0.87; I2 = 0.0 %), body weight (WMD= −0.42 kg, 95 %CI −0.84 to 0.00; P = 0.05; I2 = 0.0 %), and adiponectin levels (WMD = 0.32 μg/mL, 95 %CI −0.74 to 1.38; P = 0.55; I2 = 0.0 %). Conclusions: The current meta-analysis identified a decrease in HbA1c and an increase in LDL-cholesterol with administration of voglibose. However, no significant effect was observed on FBS, insulin, bodyweight, BMI, adiponectin, triglycerides, total- and HDL-cholesterol levels. © 2020 Elsevier Ltd